All attending UK organisations

UK companies attending UK @BIO-Europe 2025 as part of the official delegation

(Click here to search profiles):

UK Exhibitors
BioPartner UK: UK Pavilion, booth #C36

UK Pavilion (booth 36):
BIA, High Force Research, HistologiX, MediWales, RoslinCT, Scottish Development International

Other companies associated with the delegation*:
Almac Discovery, Bit Bio, DLRC, Pracipio, REPROCELL Europe, Sareum, Scendea, YAFO Capital (Shanghai).

Scotland
Aurum Biosciences, Mironid, RoslinCT, REPROCELL Europe, Scottish Development International

All attending UK companies:
1nhaler, 4basebio, 5654 & Company, A&O Shearman, AAVantgarde Bio, Abacus Medicine, Access InVivo, Accord Healthcare, Advanz Pharma SAS, Almac Discovery, Almac Group, AlphaSense, Amphista Therapeutics, Apollo Therapeutics, Aptamer Group, Arcinova, Artelo Biosciences, ASKA pharmaceutical, Astellas, AstronauTx, Asymchem Labs., Aurobindo Pharma, Autifony Therapeutics, Autolus, Avata Biosciences, AviadoBio, Babraham Institute, BAP Pharma, Barrington James, BDO LLP, BIA, Biocell, BioPartner UK, BioPharm International, BioPhorum, Biospire Japan, Bit Bio, BlackfinBio, BlackRock, Bloomberg LP, Blue Earth Therapeutics, Blue Matter, Boult Wade Tennant LLP, Breralifesciences, Brigid Bio, Bristows LLP, C4X Discovery, Caledonia Life Sciences, Cancer Research UK, Celentyx, Centauri Therapeutics, CGT Catapult, Chromatin Bioscience, Chugai Pharma, Citeline (Scrip, Pink Sheet, In Vivo), Claret Capital Partners, Clarivate, Clinigen, Clock Bio, Coding Bio, Conversis, Cooley LLP, Coulter Partners, Crucible Therapeutics, Curia Global Inc, Curve Therapeutics, Cytospire Therapeutics, Deep Science Ventures, Dia Beta Labs, DLRC, e-therapeutics, Eisai Co., Elanco Animal Health, Eli Lilly, Enhanced Genomics, Epsilogen, Esperante Ventures, Essential Pharma, Evaluate Pharma/ Nature portfolio, Evestia Clinical, Evonik, Evox Therapeutics, Exogene, F2G Biotech GmbH, Fingerpost Consultin, Fusion Antibodie, Galen Pharma, Glen Clova Scientific, GlobalData, Gowling WLG LLP, GreyRigge Associates, Greywolf Therapeutics, GSK, Guidepoint, Hammersmith Medicines Research, a Nucleus Network Company, Harness Therapeutics, Harvest Integrated Research Organization (HiRO), High Force Research, HistologiX, Houdini Bio, HungaroTrial, Hunter Healthcare, hVIVO, Ignota Labs, Immunokey, Immupharma, IMU Biosciences, Inceptua Early Access, Informa - BPI, Informa – EBD Group, Informa – partneringONE, Insmed, Intract Pharma, Intralink, Ipsen, IQVIA, Isogenica, IsomAb, Isomorphic Labs, Jo Shorthouse, Johnson & Johnson Innovation, Kadans Science Partner, Kesmalea, KIFFIK Biomedical, Inc., klas therapeutics, Kyowa Kirin, L1 Health, Labcorp Early Development, LabGenius Therapeutics, Lane Clark & Peacock, Larkspur International, Laverock Therapeutics, Life Sciences Recruitment, LifeArc, Lightning Health, Lindus Health, Lonza AG, Macomics., Medherant, Medical Incubator Japan, Medicilon UK/EU Office, Medicines Discovery Catapult, MediWales, Meet Life Sciences, Merck Healthcare KGaA, Mereo BioPharma Group, Mergermarket, Merxin, Mironid, Mishcon de Reya, Moelis, Moredun Research Institute, MSD, MultiOmic Health, My Medical Department, Nanomerics., NanoSyrinx, Nanovery, National Institute for Health and Care Research, National Institute for Health and Care Research (NIHR), Neuracle Genetics Inc., Norgine, Norman Broadbent Executive Search, Norstella, Northway Biotech, Novartis AG, NRG Therapeutics, Nucleome Therapeutics, Nxera Pharma, OBN UK, Ochre Bio, Octapharma Handelsgesellschaft mbH, OKYO Pharma, Oncobayes Alpha, OncoBone Therapeutics, One Nucleus, Ono Pharmaceutical, Onyx Scientific, Optimum Strategic Communications, Orbit Discovery, Osborne Clarke LLP, Ossianix, Otsuka, Outrun Therapeutics, OutSee, Oxford Biomedica, Oxford BioTherapeutics, Oxford Medical Products, Oxford Science Enterprises, Oxford University Innovation, Pathios Therapeutics, Pencil Biosciences, PentaBind, PharmaCircle, PharmaVentures, PharmaVentures Pricing & Market Access, PharmEnable Therapeutics, PhoreMost, Pleco Therapeutics, PNAS Therapeutics, Pracipio, Premier Research, Present Value, ProImmune., Prokarium, ProPharma, Queen Mary University of London, Quell Therapeutics, ramarketing PR., Re-Vana Therapeutics, ReNewVax, Reprocell Europe, Research Donors., Revvity, RoslinCT, Rothschild and Co., RoukenBio, Russell Reynolds Associates, RxCelerate, Sage Healthcare, Sano Genetics, Sareum, Scendea., SCI Ventures, Sciensus, Scius Communications, Sekisui Diagnostics UK, SERB Pharmaceuticals, Serenatis Bio, SGS Vitrology, Shield Therapeutics, Shionogi & Co.,., Simcere Pharmaceutical Group, SLA Pharma, Sofinnova Partners, Soterios, Stablepharma, Stephenson Harwood LLP, Stifel Financial Corp., StoneCalibre, SV Health Investors' Dementia Discovery Fund, Sygnature Discovery, Symbiosis, Synaptix Bio, Syncona Investment Management, SynGenSys, T-Cypher Bio, T-Therapeutics, Tailor Bio, Tay Therapeutics, Team Consulting, Tessellate Bio, The Cambridge Crystallographic Data Centre, The DPO Centre, The Francis Crick Institute, The Group, The Science Behind, The University of Manchester, TheraCryf, Therakind, Tiziana Life Sciences, TMC Pharma Services, Topia Life sciences, TOPIA PHARMA INTELLIGENCE, Trade and Invest British Columbia, Treos Bio, Trogenix, Turbine Simulated Cell Technologies., UCLB, UK Health Security Agency, Ulster University, Uniphar, University of Bradford, University of Edinburgh, University of Glasgow, Upperton Pharma Solutions, VacV Biotherapeutics UK, Vernalis, Vianautis Bio, Viatris, Virax Biolabs, Virdisgroup, Virothera, Weatherden, Wickenstones, Wittkieffer, WuXi Biologics, Xterna, Zura Bio

(369)

Join them here!